Van ECK Associates Corp Purchases 2,258 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Van ECK Associates Corp increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 38.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 8,205 shares of the company’s stock after purchasing an additional 2,258 shares during the period. Van ECK Associates Corp’s holdings in Medpace were worth $2,515,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of MEDP. Wellington Management Group LLP lifted its stake in shares of Medpace by 312.6% during the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after buying an additional 319,210 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Medpace by 67.6% during the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after acquiring an additional 246,775 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of Medpace in the third quarter valued at approximately $30,252,000. International Assets Investment Management LLC increased its stake in shares of Medpace by 248,773.8% during the fourth quarter. International Assets Investment Management LLC now owns 104,527 shares of the company’s stock worth $32,041,000 after purchasing an additional 104,485 shares during the period. Finally, Lord Abbett & CO. LLC lifted its holdings in Medpace by 682.8% during the 3rd quarter. Lord Abbett & CO. LLC now owns 114,588 shares of the company’s stock worth $27,745,000 after purchasing an additional 99,949 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insiders Place Their Bets

In other news, CEO August J. Troendle sold 15,102 shares of the firm’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the transaction, the chief executive officer now owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares in the company, valued at $6,117,943. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 15,102 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the transaction, the chief executive officer now owns 791,541 shares in the company, valued at approximately $317,162,563.29. The disclosure for this sale can be found here. Insiders have sold 204,442 shares of company stock valued at $82,702,867 in the last ninety days. 20.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have commented on MEDP shares. Guggenheim upped their price objective on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 price objective for the company. StockNews.com upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. Robert W. Baird lifted their price target on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Finally, UBS Group upgraded Medpace from a “neutral” rating to a “buy” rating and boosted their price target for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $443.00.

Medpace Stock Up 0.3 %

MEDP stock opened at $402.10 on Wednesday. The company’s 50-day moving average price is $398.00 and its two-hundred day moving average price is $334.20. The firm has a market cap of $12.46 billion, a P/E ratio of 40.99, a P/E/G ratio of 1.95 and a beta of 1.40. Medpace Holdings, Inc. has a 12 month low of $197.39 and a 12 month high of $421.00.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. The business had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm’s quarterly revenue was up 17.7% compared to the same quarter last year. During the same period last year, the firm posted $2.27 earnings per share. Equities analysts predict that Medpace Holdings, Inc. will post 11.23 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.